Giovanni Caforio, Bristol Myers Squibb CEO (Christopher Goodney/Bloomberg via Getty Images)

November 16, 2020 04:59 PM ESTUpdated November 17, 02:48 PM

Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel application yet again

The CVR ($BMYRT) tied to Bristol Myers Squibb’s big Celgene buyout took one more step right to the brink Monday afternoon.

As some …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Bris­tol My­er­s' $9 Cel­gene CVR is tee­ter­ing on the brink of dis­as­ter as the FDA de­lays the liso-cel ap­pli­ca­tion yet again